Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Posterior reversible leukoencephalopathy syndrome secondary to hepatic transarterial chemoembolization with doxorubicin drug eluting beads.

Kistler CA, McCall JC, Ghumman SS, Ali IA, Siddiqui AA.

J Gastrointest Oncol. 2014 Apr;5(2):E43-5. doi: 10.3978/j.issn.2078-6891.2014.011.

2.

Transarterial chemoembolization of liver metastases from well differentiated gastroenteropancreatic endocrine tumors with doxorubicin-eluting beads: preliminary results.

de Baere T, Deschamps F, Teriitheau C, Rao P, Conengrapht K, Schlumberger M, Leboulleux S, Baudin E, Hechellhammer L.

J Vasc Interv Radiol. 2008 Jun;19(6):855-61. doi: 10.1016/j.jvir.2008.01.030. Epub 2008 Mar 19.

PMID:
18503899
3.

Transarterial chemoembolization using drug eluting beads for the treatment of hepatocellular carcinoma: Now and future.

Woo HY, Heo J.

Clin Mol Hepatol. 2015 Dec;21(4):344-8. doi: 10.3350/cmh.2015.21.4.344. Epub 2015 Dec 24. Review.

4.

Intra-arterial hepatic chemoembolization (TACE) of liver metastases from ocular melanoma with slow-release irinotecan-eluting beads. Early results of a phase II clinical study.

Fiorentini G, Aliberti C, Del Conte A, Tilli M, Rossi S, Ballardini P, Turrisi G, Benea G.

In Vivo. 2009 Jan-Feb;23(1):131-7.

5.

Unusual case of intra-arterial doxorubicin chemoembolization-associated posterior reversible encephalopathy syndrome.

Pawar PS, Noviawaty I, Zaidat OO.

Neurologist. 2012 Jan;18(1):49-50. doi: 10.1097/NRL.0b013e318235a06d.

PMID:
22217617
6.

Transarterial Chemoembolization of Liver Metastases from Uveal Melanoma Using Irinotecan-Loaded Beads: Treatment Response and Complications.

Carling U, Dorenberg EJ, Haugvik SP, Eide NA, Berntzen DT, Edwin B, Dueland S, Røsok B.

Cardiovasc Intervent Radiol. 2015 Dec;38(6):1532-41. doi: 10.1007/s00270-015-1093-4. Epub 2015 Apr 2.

PMID:
25832764
7.

Imaged guided transarterial chemoembolization with drug-eluting beads loaded with doxorubicin (DEBDOX) for hepatic metastases from melanoma: early outcomes from a multi-institutional registry.

Brown RE, Gibler KM, Metzger T, Trofimov I, Krebs H, Romero FD, Scoggins CR, McMasters KM, Martin RC 2nd.

Am Surg. 2011 Jan;77(1):93-8.

PMID:
21396314
8.
9.

[Economic impact of transarterial chemoembolization with drug eluting beads in the treatment of hepatocellular carcinoma].

Malbranche C, Boulin M, Guiu B, Pernot C, Cercueil JP, Serge Aho L, Musat A, Bedenne L, Hillon P, Guignard MH, Fagnoni P.

Bull Cancer. 2011 Jun;98(6):671-8. doi: 10.1684/bdc.2011.1370. French.

10.

Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma.

Prajapati HJ, Dhanasekaran R, El-Rayes BF, Kauh JS, Maithel SK, Chen Z, Kim HS.

J Vasc Interv Radiol. 2013 Mar;24(3):307-15. doi: 10.1016/j.jvir.2012.11.026. Epub 2013 Jan 29.

PMID:
23375519
11.

Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics.

Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, Ayuso C, Castells L, Montañá X, Llovet JM, Bruix J.

J Hepatol. 2007 Mar;46(3):474-81. Epub 2006 Nov 29.

PMID:
17239480
12.

Transarterial hepatic chemoembolization with 70-150 µm drug-eluting beads: assessment of clinical safety and liver toxicity profile.

Odisio BC, Ashton A, Yan Y, Wei W, Kaseb A, Wallace MJ, Vauthey JN, Gupta S, Tam AL.

J Vasc Interv Radiol. 2015 Jul;26(7):965-71. doi: 10.1016/j.jvir.2015.03.020. Epub 2015 Jun 5.

13.

Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma.

Huang K, Zhou Q, Wang R, Cheng D, Ma Y.

J Gastroenterol Hepatol. 2014 May;29(5):920-5. doi: 10.1111/jgh.12439.

PMID:
24224722
14.

Chemoembolization with drug eluting beads preloaded with irinotecan (DEBIRI) vs doxorubicin (DEBDOX) as a second line treatment for liver metastases from cholangiocarcinoma: a preliminary study.

Venturini M, Sallemi C, Agostini G, Marra P, Cereda S, Reni M, Aldrighetti L, De Cobelli F, Del Maschio A.

Br J Radiol. 2016 Nov;89(1067):20160247. Epub 2016 Sep 16.

PMID:
27558984
15.

Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma: comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study.

Lee S, Kim KM, Lee SJ, Lee KH, Lee DY, Kim MD, Kim DY, Kim SU, Won JY.

Acta Radiol. 2017 Feb;58(2):131-139. doi: 10.1177/0284185116648501. Epub 2016 Jul 12.

PMID:
27217418
16.

Doxorubicin-loaded drug-eluting beads versus conventional transarterial chemoembolization for nonresectable hepatocellular carcinoma.

Arabi M, BenMousa A, Bzeizi K, Garad F, Ahmed I, Al-Otaibi M.

Saudi J Gastroenterol. 2015 May-Jun;21(3):175-80. doi: 10.4103/1319-3767.157571. Erratum in: Saudi J Gastroenterol. 2015 Jul-Aug;21(4):264.

17.

A lethal complication after transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma.

Toro A, Bertino G, Arcerito MC, Mannnino M, Ardiri A, Patane' D, Di Carlo I.

Case Rep Surg. 2015;2015:873601. doi: 10.1155/2015/873601. Epub 2015 Feb 23.

18.

Chemoembolization of hepatocellular carcinoma with drug-eluting beads complicated by interstitial pneumonitis.

Aladdin M, Ilyas M.

Semin Intervent Radiol. 2011 Jun;28(2):218-21. doi: 10.1055/s-0031-1280668.

19.

[Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma].

Ferrer Puchol MD, la Parra C, Esteban E, Vaño M, Forment M, Vera A, Cosín O.

Radiologia. 2011 May-Jun;53(3):246-53. doi: 10.1016/j.rx.2010.07.010. Epub 2011 Feb 4. Spanish.

20.

Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma.

Song MJ, Chun HJ, Song DS, Kim HY, Yoo SH, Park CH, Bae SH, Choi JY, Chang UI, Yang JM, Lee HG, Yoon SK.

J Hepatol. 2012 Dec;57(6):1244-50. doi: 10.1016/j.jhep.2012.07.017. Epub 2012 Jul 20.

PMID:
22824821

Supplemental Content

Support Center